Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Reuters NewMedia - Saturday October 25, 2003
WHO will support distributing the pills, which could violate drug company patents, as part of a plan to get the lifesaving drugs to poor people, the newspaper said.
One of the generic combination pills is being made by a drug company in India, Cipla Ltd, and is sold there and in Africa for less than a dollar a day.
More than 40 million people worldwide are infected with the AIDS virus, which is incurable and always fatal. More than 25 million have died of AIDS.
Drugs can keep the virus under control, but they are expensive and out of the reach of all but a few of the people who are infected. Most patients live in Africa and have little access to health care.
WHO wants to change this and get drugs to 3 million people in targeted areas.
WHO officials and AIDS groups have been negotiating with the companies that make HIV medicines to persuade them to lower prices and to allow generic copies to be distributed without challenge.
In August the International Federation of Pharmaceutical Manufacturers Associations approved a World Trade Organization deal under which poor states with no drugs industry would be able to buy cheap generics.
In return they must ensure none of these products end up on profitable Western markets where patents are strictly enforced.
On Thursday four generic drug companies agreed to make HIV drugs available to millions of people in African and Caribbean nations at about half the current price.
Former U.S. President Bill Clinton help negotiate the deal under which generic drugs would be offered at $140 per person a year.
The drugs are not a cure but can control the virus so patients can lead near-normal lives. They may also make patients somewhat less likely to pass the virus to others.
031025
RE031032
Copyright © 2003 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .